14Dec/13

Roche, Prothena enter pact to co-develop & market antibodies for Parkinson's … – pharmabiz.com


Economic Times

Roche, Prothena enter pact to co-develop & market antibodies for Parkinson’s
pharmabiz.com
Roche and clinical stage biotechnology company, Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of 
Roche, Prothena to develop new antibodies for Parkinson’s disease treatmentPharmaceutical Business Review
Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing
Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co 4-traders (press release)
Zacks.com –PMLiVE
all 41 news articles »
13Dec/13

New Way to Predict Prognosis for Heart Failure Patients – Science Daily (press release)

New Way to Predict Prognosis for Heart Failure Patients
Science Daily (press release)
11, 2013 — Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism
New way to predict prognosis in patients with heart failureScience Codex

all 7 news articles »